Drug development company Nobex Corp. says exploratory clinical trial for its oral insulin were encouraging.
The news was published in the January edition of the peer-reviewed scientific journal Metabolism.
This Phase I/II clinical trial was one of the initial studies to investigate the safety and tolerability of a single oral dose of a modified human insulin in patients with type 1 diabetes mellitus.
Nobex’s lead modified insulin product, known as Hexyl-insulin monoconjugate 2 (HIM2), is an orally-active insulin that has reached Phase II clinical development for the treatment of patients with diabetes mellitus.
The results of the study published in Metabolism, Nobex says, suggest that oral HIM2, when added to a basal insulin regimen, was safe and may prove effective in controlling postprandial hyperglycemia (a rise in glucose levels after eating) in patients with diabetes mellitus.
RTP-based Nobex says it is currently seeking pharmaceutical partners for the worldwide development and commercialization of its insulin products.
Nobex Corp.: www.nobexcorp.com
